Yara Abdou, MD
Hematology & Oncology · Albuquerque, NMNPI 1578981114
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $23,078 of the $24,941 with a category attached, or 92.5%. AstraZeneca accounts for 75.3% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $10,880, more than ten times the $278 reported in 2019. Among hematology & oncology clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 26 payments — averaging $959.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$19K
- Tersera Therapeutics LLC$3K
- Pfizer$2K
- Covis Pharma GmbH$200
- Ipsen Biopharmaceuticals, Inc$146
- Blueprint Medicines Corporation$98
- plus $291 from 5 others
Across 26 payments — averaging $10,413 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Blueprint Medicines Corporation$146K
- Merck$70K
- Pfizer$46K
- Sanofi US Services Inc.$7K
- Novartis$1K
What the payments were for
- Consulting fees$23,07893%
- Travel & lodging$9014%
- Food & beverage$8744%
- Education$880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 9 | $18,775 |
| Tersera Therapeutics LLC | 5 | $2,965 |
| Pfizer | 4 | $2,466 |
| Covis Pharma GmbH | 1 | $200 |
| Ipsen Biopharmaceuticals, Inc | 1 | $146 |
| Blueprint Medicines Corporation | 1 | $98 |
| Daiichi Sankyo Inc. | 1 | $95 |
| Astellas Pharma US Inc | 1 | $70 |
| Incyte Corporation | 1 | $62 |
| Gilead | 1 | $46 |
| Merck | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,941 in reported general payments places this provider in the 90th percentile of 54 hematology & oncology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 14 | $214,765 |
| Letrozole | 51 | $947 |
| Tamoxifen Citrate | 18 | $381 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Albuquerque
- Ursa Brown GlabermanAlbuquerque$219K
- Neda Hashemi SadraeiAlbuquerque$96K
- Muhammad TarakjiAlbuquerque$34K
- George AtwehAlbuquerque$24K
- Scott HerbertAlbuquerque$14K
- Jose AvitiaAlbuquerque$11K
- Zoneddy DayaoAlbuquerque$10K
- Toufic TannousAlbuquerque$10K
- Amy TarnowerAlbuquerque$5K
- Bernard TawfikAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.